Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism - Cancer Currents Blog

National Cancer Institute sent this bulletin at 07/05/2023 10:43 AM EDT

Having trouble viewing this email? View it as a Web page.

Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism
07/05/2023
	In the ADAURA clinical trial, people with early-stage lung cancer treated with osimertinib (Tagrisso) after surgery lived longer than people treated with a placebo after surgery. Despite some criticisms about its design, the trial is expected to change patient care.

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.